The current landscape of long COVID clinical trials: NIH’s RECOVER to Stanford Medicine’s STOP-PASC initiative
Chiranjib Chakraborty, Manojit Bhattacharya
Abstract
The US National Institutes of Health (NIH) officially announced intent to evaluate therapeutics against long COVID on July 31, 2023. The trial will be conducted through the RECOVER (Researching COVID to Enhance Recovery) initiative to evaluate the safety and efficacy of therapies against long COVID. They will evaluate four potential treatments for long COVID through clinical trials. They will also explore seven additional treatments for long COVID in the future. Recently, Kozlov reported in Nature News about the NIH’s RECOVER initiative.
Topics & Concepts
Coronavirus disease 2019 (COVID-19)Clinical trialMedicineAlternative medicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakFamily medicineMedical educationInternal medicineVirologyPathologyOutbreakInfectious disease (medical specialty)DiseaseLong-Term Effects of COVID-19Neuroinflammation and Neurodegeneration MechanismsIntensive Care Unit Cognitive Disorders